Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
What to Know If Taking Weight Loss Drugs Like Ozempic - Featured image
GLP-1 Medications

What to Know If Taking Weight Loss Drugs Like Ozempic

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·April 8, 2026·5 min read

On this page

  • What Are GLP-1 Weight Loss Drugs Like Ozempic and Mounjaro?
  • The Rapid Rise in Australia: Half a Million Users
  • Life-Changing Benefits vs. Side Effects: A Balanced View
  • Expert Insights: Professor Kelly Lambert on GLP-1 Drugs
  • Who Should Consider Ozempic or Mounjaro? Practical Guidance
  • Safety, Long-Term Use, and Monitoring
  • Key Takeaways: What This Means for Patients
  • Conclusion
  • How Do They Work for Weight Loss?
  • Managing Side Effects Effectively
  • Ozempic vs. Mounjaro: Quick Comparison

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Roughly half a million Australians are using GLP-1 weight loss drugs like Ozempic and Mounjaro, with some reporting life-changing results while others face side effects. Professor Kelly Lambert from the University of Wollongong shares key insights on what you need to know. This guide covers mechanisms, safety, and practical tips for users.

Share

On this page

  • What Are GLP-1 Weight Loss Drugs Like Ozempic and Mounjaro?
  • The Rapid Rise in Australia: Half a Million Users
  • Life-Changing Benefits vs. Side Effects: A Balanced View
  • Expert Insights: Professor Kelly Lambert on GLP-1 Drugs
  • Who Should Consider Ozempic or Mounjaro? Practical Guidance
  • Safety, Long-Term Use, and Monitoring
  • Key Takeaways: What This Means for Patients
  • Conclusion
  • How Do They Work for Weight Loss?
  • Managing Side Effects Effectively
  • Ozempic vs. Mounjaro: Quick Comparison

Weight loss drugs like Ozempic have surged in popularity, with roughly half a million Australians now using GLP-1 medications such as Ozempic and Mounjaro to shed pounds. While some users describe the effects as nothing short of life-changing, others experience side effects that require careful management. So, what do you need to know if you're taking these drugs? Professor Kelly Lambert, Professor and Discipline Leader for Nutrition Science and Nutrition at The University of Wollongong, joins Suzanne Hill to discuss losing weight with the aid of these medications. This comprehensive guide expands on these key topics, providing clinical context, mechanisms, and patient guidance.

What Are GLP-1 Weight Loss Drugs Like Ozempic and Mounjaro?

GLP-1 receptor agonists, or GLP-1 drugs, mimic the glucagon-like peptide-1 hormone, which regulates blood sugar and appetite. Ozempic (semaglutide) was originally approved for type 2 diabetes but gained fame for weight loss due to its ability to slow gastric emptying, increase satiety, and reduce calorie intake. Mounjaro (tirzepatide), a dual GLP-1 and GIP agonist, works similarly but targets two hormones for potentially greater weight loss effects.

These injectable weekly medications have transformed obesity management. Clinical trials show average weight reductions of 15-20% over 68 weeks, making them a powerful tool when diet and exercise fall short. However, they are prescription-only and best suited for those with BMI over 30 or weight-related conditions.

How Do They Work for Weight Loss?

  • Appetite suppression: Signals the brain to feel full sooner.
  • Slower digestion: Delays stomach emptying, stabilizing blood sugar.
  • Calorie reduction: Users naturally eat 20-30% fewer calories without hunger.

Understanding this mechanism helps explain why the drugs deliver sustained results, but success depends on lifestyle integration.

The Rapid Rise in Australia: Half a Million Users

In Australia, demand for Ozempic and Mounjaro has exploded, with roughly half a million people now relying on these GLP-1 drugs for weight loss. This surge reflects growing awareness of obesity as a chronic condition affecting over 2 in 5 adults. Shortages have even prompted government interventions to prioritize diabetes patients.

While access has improved via the Pharmaceutical Benefits Scheme for eligible users, off-label weight loss prescriptions remain common. This trend underscores the drugs' appeal but highlights the need for informed use amid high costs (around AUD 130-300 weekly without subsidy).

Life-Changing Benefits vs. Side Effects: A Balanced View

Many users report profound transformations: significant weight loss, improved mobility, better sleep, and boosted confidence. Beyond aesthetics, these drugs reduce risks for heart disease, stroke, and type 2 diabetes by addressing metabolic roots of obesity.

However, side effects affect up to 40% of users, ranging from mild to disruptive:

  • Gastrointestinal: Nausea (20-44%), vomiting, diarrhea, constipation—often worst in weeks 1-4.
  • Other: Fatigue, headache, low blood sugar (if diabetic), gallbladder issues (rare).

Managing Side Effects Effectively

Start low and titrate slowly (e.g., Ozempic from 0.25mg to 2.4mg). Eat small, protein-rich meals; stay hydrated; avoid fatty foods. Most symptoms resolve within months. Tools like Shotlee can help track symptoms, side effects, or injection schedules for better doctor discussions.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Serious risks like pancreatitis or thyroid tumors are rare (<1%), but monitor for severe abdominal pain or vision changes.

Expert Insights: Professor Kelly Lambert on GLP-1 Drugs

Professor Kelly Lambert, a leading nutrition expert at The University of Wollongong, emphasizes evidence-based use of these drugs. In her discussion with Suzanne Hill, she addresses practical aspects of losing weight with GLP-1 aids, including integration with diet, exercise, and long-term sustainability. Her research in nutrition science highlights the importance of multidisciplinary care to maximize benefits and minimize risks.

Key themes from experts like Prof. Lambert include:

  • Combining drugs with behavioral changes for lasting results post-discontinuation.
  • Monitoring nutrient intake to prevent muscle loss or deficiencies.
  • Personalized dosing based on response and tolerance.

Who Should Consider Ozempic or Mounjaro? Practical Guidance

These drugs suit adults with obesity or overweight plus comorbidities (e.g., hypertension, prediabetes). Not ideal for short-term cosmetic use or those with history of medullary thyroid cancer, pancreatitis, or pregnancy.

What to Discuss with Your Doctor:

  1. Medical history and current meds (avoid with insulin without adjustment).
  2. Expected weight loss timeline (plateaus common after 6-12 months).
  3. Alternatives like Wegovy (higher-dose semaglutide) or orlistat.
  4. Stopping strategy: Weight regain averages 2/3 without maintenance.

Ozempic vs. Mounjaro: Quick Comparison

DrugActive IngredientWeight Loss (Avg.)Cost (Weekly)
OzempicSemaglutide15%AUD 130-200
MounjaroTirzepatide20-22%AUD 200-300

Mounjaro may edge out for greater loss, but individual response varies.

Safety, Long-Term Use, and Monitoring

Australian Therapeutic Goods Administration approves these for diabetes; weight loss is off-label but supported by data. Long-term studies (up to 2 years) show sustained efficacy with monitoring. Annual checks for kidney function, bone density, and mental health are advised, as rapid loss stresses the body.

Pregnancy: Stop 2 months prior. Breastfeeding: Consult physician.

Key Takeaways: What This Means for Patients

  • GLP-1 drugs like Ozempic offer powerful weight loss for half a million Australians, but pair with lifestyle changes.
  • Expect side effects early; manage proactively.
  • Seek expert guidance like Prof. Kelly Lambert's insights for optimal results.
  • Track progress and consult doctors regularly.

Conclusion

If you're taking weight loss drugs like Ozempic or Mounjaro, knowledge empowers better outcomes. From mechanisms to management, this guide equips you with actionable insights. Always prioritize professional medical advice for your unique needs.

?Frequently Asked Questions

What are common side effects of weight loss drugs like Ozempic?

Common side effects include nausea, vomiting, diarrhea, and constipation, especially early on. These often improve with time, slow dose increases, and dietary adjustments like small, bland meals.

How many Australians are using GLP-1 drugs like Ozempic and Mounjaro?

Roughly half a million Australians are currently using these drugs for weight loss, reflecting their growing popularity amid obesity challenges.

Who is Professor Kelly Lambert and what does she say about GLP-1 drugs?

Professor Kelly Lambert is Discipline Leader for Nutrition Science at The University of Wollongong. She discusses key aspects of using GLP-1 drugs like Ozempic for weight loss, emphasizing evidence-based integration with diet and lifestyle.

What should I discuss with my doctor before starting Ozempic?

Discuss your medical history, BMI, comorbidities, potential interactions, dosing plan, and monitoring for side effects or long-term risks.

How do Ozempic and Mounjaro differ for weight loss?

Ozempic (semaglutide) averages 15% weight loss; Mounjaro (tirzepatide) up to 22%. Both are weekly injections, but Mounjaro targets two hormones for potentially stronger effects.

Source Information

Originally published by Australian Broadcasting Corporation.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Ozempic

All Ozempic articles →
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

More in GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

5 min read
Novo's Woes Despite Ozempic's Explosive Growth
GLP-1 Medications

Novo's Woes Despite Ozempic's Explosive Growth

Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.

5 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
GLP-1 Medications

South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs

One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.

4 min read
Share this article
  1. Home
  2. Blog
  3. What to Know If Taking Weight Loss Drugs Like Ozempic
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community